ADMA Biologics, Inc. Quarterly report pursuant to sections 13 or 15(d)

Quarterly report pursuant to sections 13 or 15(d)

6. SEGMENTS (Tables)

6. SEGMENTS (Tables)

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Three Months Ended March 31, 2013		Plasma Collection Center				Research and Development				Corporate				Consolidated

Revenues		$	792,935			$	-			$	-			$	792,935

Cost of sales			529,046				-				-				529,046

Gross profit			263,889				-				-				263,889

Loss from operations			(251,399	)			(1,467,584	)			(1,431,106	)			(3,150,089	)

Other expense			-				-				(91,558	)			(91,558	)

Loss before income taxes			(251,399	)			(1,467,584	)			(1,522,664	)			(3,241,647	)

Property and equipment, net			708,994				5,131				87,632				801,757

Depreciation and amortization expense			36,833				836				5,944				43,613

Three Months Ended March 31, 2012		Plasma Collection Center				Research and Development				Corporate				Consolidated

Revenues		$	4,400			$	-			$	-			$	4,400

Cost of sales			2,200				-				-				2,200

Gross profit			2,200				-				-				2,200

Loss from operations			(457,093	)			(81,820	)			(674,589	)			(1,213,502	)

Other expense			-				-				(1,427	)			(1,427	)

Loss before income taxes			(457,093	)			(81,820	)			(676,016	)			(1,214,929	)

Property and equipment, net			781,765				24,724				8,708				815,197

Depreciation and amortization expense			40,500				4,200				1,035				45,735